Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg.

Kelly AS, Arslanian S, Hesse D, Iversen AT, Körner A, Schmidt S, Sørrig R, Weghuber D, Jastreboff AM

Obesity (Silver Spring, Md.)9 Jul 2023Cited by 37 (Europe PMC)

PMID37196421DOI10.1002/oby.23808PepBankPUB-37196421

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, 44.9% of those on semaglutide 2.4 mg reached a normal-weight or overweight BMI category at week 68, versus 12.1% on placebo.
In plain wordsIn adolescents with obesity, more of those on semaglutide 2.4 mg moved to a lower BMI category than those on placebo.
Peptide
Semaglutide
Outcome
IncreaseReclassification to normal-weight or overweight BMI category at week 68
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Participants reclassified, semaglutide
44.9%
week 68
Participants reclassified, placebo
12.1%
week 68
Odds ratio
22.7
semaglutide vs placebo
Source sentences
Summary
In the overall population, 44.9% of participants receiving semaglutide achieved weight reduction resulting in reclassification to a normal-weight or overweight BMI category versus 12.1% receiving placebo at week 68 (odds ratio: 22.7; 95% CI: 7.6-67.9).
1 context sentence(design, population, supporting numbers)
Summary · context
Adolescents with obesity received once-weekly subcutaneous semaglutide 2.4 mg or placebo plus lifestyle intervention, which comprised counseling in healthy nutrition and a goal of 60 minutes of moderate- to high-intensity physical activity per day.
Report a problemFND-3719642101
02HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, the proportion in obesity class III fell from 37.3% to 13.6% with semaglutide and rose with placebo.
In plain wordsIn adolescents with obesity, fewer on semaglutide were in the most severe obesity class, while more on placebo were.
Peptide
Semaglutide
Outcome
DecreaseProportion in obesity class III
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Obesity class III proportion, baseline
37.3%
semaglutide
Obesity class III proportion, week 68
13.6%
semaglutide
Source sentences
Summary
The proportion of semaglutide-treated participants in obesity class III decreased from 37.3% to 13.6% but increased with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adolescents with obesity received once-weekly subcutaneous semaglutide 2.4 mg or placebo plus lifestyle intervention, which comprised counseling in healthy nutrition and a goal of 60 minutes of moderate- to high-intensity physical activity per day.
Report a problemFND-3719642102
03HumanRandomized controlled trialEfficacy outcome
In adolescents with obesity, 73.7% of those on semaglutide 2.4 mg improved by at least one BMI category, versus 19.0% on placebo.
In plain wordsIn adolescents with obesity, more of those on semaglutide 2.4 mg improved by at least one BMI category than those on placebo.
Peptide
Semaglutide
Outcome
IncreaseImprovement of at least one BMI category
Study
n: not reported in source
Comparator
Placebo
Analysis
Exploratory
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg once weekly · subcutaneous · 68 weeksAs given in this study (human).
Measurements
Improved by at least one BMI category, semaglutide
73.7%
week 68
Improved by at least one BMI category, placebo
19%
week 68
Odds ratio
23.5
semaglutide vs placebo
Source sentences
Summary
The odds ratio for achieving an improvement of at least one BMI category was significantly greater with semaglutide versus placebo (23.5; 95% CI: 9.9-55.5); an improvement of at least one BMI category was seen in 73.7% of participants receiving semaglutide compared with 19.0% of participants receiving placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Adolescents with obesity received once-weekly subcutaneous semaglutide 2.4 mg or placebo plus lifestyle intervention, which comprised counseling in healthy nutrition and a goal of 60 minutes of moderate- to high-intensity physical activity per day.
Report a problemFND-3719642103

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04102189

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Novo Nordisk A/Sn = 2017 Oct 2019 to 28 Mar 2022

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 11 Dec 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.